NOT FOR DISTRIBUTION
Header cover image

Market Cap

US$837.0m

Last Updated

2021/05/08 22:50 UTC

Data Sources

Company Financials +

Executive Summary

Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the treatment of liver and respiratory care diseases. More Details


Snowflake Analysis

Excellent balance sheet with high growth potential.

Share Price & News

How has Arcturus Therapeutics Holdings's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: ARCT is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 11% a week.

Volatility Over Time: ARCT's weekly volatility has decreased from 19% to 11% over the past year.


Market Performance


7 Day Return

-13.3%

ARCT

-3.8%

US Biotechs

-0.3%

US Market


1 Year Return

-18.9%

ARCT

24.4%

US Biotechs

50.2%

US Market

Return vs Industry: ARCT underperformed the US Biotechs industry which returned 24.4% over the past year.

Return vs Market: ARCT underperformed the US Market which returned 50.2% over the past year.


Shareholder returns

ARCTIndustryMarket
7 Day-13.3%-3.8%-0.3%
30 Day-15.6%1.1%2.2%
90 Day-62.6%-11.1%3.8%
1 Year-18.9%-18.9%26.3%24.4%52.7%50.2%
3 Year458.9%458.9%26.9%20.4%63.4%53.1%
5 Yearn/a55.7%43.3%129.6%104.0%

Long-Term Price Volatility Vs. Market

How volatile is Arcturus Therapeutics Holdings's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Arcturus Therapeutics Holdings undervalued compared to its fair value and its price relative to the market?

2.1x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate ARCT's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate ARCT's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: ARCT is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: ARCT is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ARCT's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ARCT is good value based on its PB Ratio (2.1x) compared to the US Biotechs industry average (3.5x).


Future Growth

How is Arcturus Therapeutics Holdings forecast to perform in the next 1 to 3 years based on estimates from 11 analysts?

49.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ARCT is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).

Earnings vs Market: ARCT is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: ARCT's is expected to become profitable in the next 3 years.

Revenue vs Market: ARCT's revenue (41.2% per year) is forecast to grow faster than the US market (9.1% per year).

High Growth Revenue: ARCT's revenue (41.2% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if ARCT's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Arcturus Therapeutics Holdings performed over the past 5 years?

-42.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ARCT is currently unprofitable.

Growing Profit Margin: ARCT is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ARCT is unprofitable, and losses have increased over the past 5 years at a rate of 42.7% per year.

Accelerating Growth: Unable to compare ARCT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ARCT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-11.6%).


Return on Equity

High ROE: ARCT has a negative Return on Equity (-18.19%), as it is currently unprofitable.


Financial Health

How is Arcturus Therapeutics Holdings's financial position?


Financial Position Analysis

Short Term Liabilities: ARCT's short term assets ($467.8M) exceed its short term liabilities ($49.5M).

Long Term Liabilities: ARCT's short term assets ($467.8M) exceed its long term liabilities ($30.4M).


Debt to Equity History and Analysis

Debt Level: ARCT's debt to equity ratio (3.8%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if ARCT's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ARCT has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: ARCT has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 56.4% each year


Dividend

What is Arcturus Therapeutics Holdings's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ARCT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ARCT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ARCT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ARCT's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ARCT's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.7yrs

Average management tenure


CEO

Joe Payne (48 yo)

8.17yrs

Tenure

US$1,165,818

Compensation

Mr. Joseph E. Payne, also known as Joe, M.Sc., has been Independent Non-Executive Director of Vallon Pharmaceuticals, Inc. since June 22, 2018. Mr. Payne has been Director of Arcturus since November 2017. ...


CEO Compensation Analysis

Compensation vs Market: Joe's total compensation ($USD1.17M) is below average for companies of similar size in the US market ($USD2.36M).

Compensation vs Earnings: Joe's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: ARCT's management team is considered experienced (2.7 years average tenure).


Board Members

Experienced Board: ARCT's board of directors are not considered experienced ( 1.7 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 32.3%.


Top Shareholders

Company Information

Arcturus Therapeutics Holdings Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Arcturus Therapeutics Holdings Inc.
  • Ticker: ARCT
  • Exchange: NasdaqGM
  • Founded: 2013
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$836.985m
  • Shares outstanding: 26.32m
  • Website: https://www.arcturusrx.com

Number of Employees


Location

  • Arcturus Therapeutics Holdings Inc.
  • 10628 Science Center Drive
  • Suite 250
  • San Diego
  • California
  • 92121
  • United States

Listings


Biography

Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the treatment of liver and respiratory care diseases. Its preclinical drug discovery and development programs include LUNAR-OTC dev...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/05/08 22:50
End of Day Share Price2021/05/07 00:00
Earnings2020/12/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.